Abbott Laboratories (ABLD.XC)
| Previous close | 99.42 |
| Open | 99.42 |
| Bid | 0.00 x 0 |
| Ask | 95.91 x 0 |
| Day's range | 99.42 - 99.42 |
| 52-week range | 87.58 - 104.98 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 172.954B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 33.70 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.03 (2.05%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
- PR Newswire
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
- PR Newswire
Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefi
